Last reviewed · How we verify

NCT04326231

Cognoa Autism Spectrum Disorder (ASD) Digital Therapeutic Engagement and Usability Study

Terminated NA Results posted Last updated 21 September 2023
What this trial tests

NA trial testing Usability assessment of Cognoa ASD Therapeutic Device in Autism Spectrum Disorder in 10 participants. Terminated before completion.

Timeline
17 March 2020
Primary endpoint
31 July 2020
31 July 2020

Quick facts

Lead sponsorCognoa, Inc.
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment10
Start date17 March 2020
Primary completion31 July 2020
Estimated completion31 July 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cognoa, Inc.

Who can join

Adults 3 to 8, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cognoa will measure usability, engagement with the device, and changes in parent-reported socialization during a 4-week period of intervention at home with the Cognoa ASD therapeutic device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Cognoa, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04326231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing